Gujarat Terce Laboratories Limited (524314) Fair Value & Analysis
Other · IN · Market cap ₹59.7M
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price −4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹30.90 – ₹56.58 · fair‑value band ₹31.43 – ₹63.05 · the ₹33.35 price screens below the ₹46.12 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gujarat Terce Laboratories Limited (524314) currently trades at ₹33.35, while our model-based Fair Value estimate is ₹46.12 — implying the stock looks roughly 38.3% undervalued today. We read business quality at 49/100 (below-average quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Gujarat Terce Laboratories Limited generated revenue of ₹356M at a net margin of 3.0%. Revenue declined 28.2% year over year. Net debt stands at ₹1.6M. The stock trades on a trailing P/E of 6.1. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Gujarat Terce Laboratories Limited manufactures and markets medical and pharmaceutical preparations in India. The company offers branded and generic formulations covering various therapeutic, such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and others. It provides its products in various forms, such as tablets, capsules, oral liquids, injections, and ointments. The company also exports its products. Gujarat Terce Laboratories Limited was founded in 1985 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Gujarat Terce Laboratories Limited reported revenue of ₹475M in FY2026 versus ₹401M in FY2022, a compound +4.3%/yr. Reported net income was ₹22.0M in FY2026, compounding +26.0%/yr from FY2022.
Is 524314 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Gujarat Terce Laboratories Limited (524314) undervalued?
What is the fair value of 524314?
What is the quality score of 524314?
What is the revenue of Gujarat Terce Laboratories Limited (524314)?
What is the net profit margin of 524314?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.